¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV Long Terminal Repeat"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • long nasopalatine nerve
    ±äÄÚÀÔõÀå½Å°æ, Àåºñ±¸°³½Å°æ
  • long QT syndrome
    ±äQTÁõÈıº
  • long thoracic nerve
    ±ä°¡½¿½Å°æ, ÀåÈä½Å°æ
  • long tract sign
    ±ä½Å°æ·Î¡ÈÄ
  • long-acting thyroid stimulator
    Áö¼Ó°©»ó»ùÀڱع°Áú, Áö¼Ó°©»ó¼±Àڱع°Áú
  • long-arm cast
    ±äÆÈ¼®°íºØ´ë
  • long-leg cast
    ±ä´Ù¸®¼®°íºØ´ë
  • long-term care
    Àå±â¿ä¾ç¼­ºñ½º
  • long-term illness
    Àå±âÁúȯ
  • long-term potentiation
    Àå±â°­È­ÀÛ¿ë
  • parasternal long axis view
    º¹Àå»ÀÁÖÀ§±äÃà´Ü¸éµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • long-acting thyroid stimulator
    Áö¼Ó¹æÆÐ»ùÀڱع°Áú, Áö¼Ó°©»ó»ùÀڱع°Áú
  • long-term potentiation
    ÀÚ±â»ó½ÂÀÛ¿ë
  • parasternal long axis view
    Èä°ñ¿¬ÀåÃà´Ü¸éµµ
  • terminal arborization
    Á¾¸»°¡Áö
  • terminal artery
    Á¾¸»µ¿¸Æ
  • bouton terminal
    Á¾¸»´ÜÃß
  • terminal bleeding
    ¹è´¢³¡¸Ó¸®ÃâÇ÷
  • terminal bronchiole
    Á¾¸»¼¼±â°üÁö
  • terminal bulb
    Á¾¸»¸Á¿ï
  • cutaneous nerve terminal
    ÇǺνŰæÁ¾¸»
  • terminal calyx
    Á¾¸»ÀÜ
  • terminal capillary
    Á¾¸»¸ð¼¼Ç÷°ü
  • terminal chlamydospore
    ¸»´ÜºñÈĸ·È¦¾¾, ¸»´ÜºñÈĸ·Æ÷ÀÚ
  • terminal cistern
    Á¾¸»¼öÁ¶
  • terminal crest
    ºÐ°è´É¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Human immunodeficiency virus = HIV
    »ç¶÷¸é¿ª°áÇ̼º ¹ÙÀÌ·¯½º
  • LATS =long acting thyroid stimulator
    Áö¼Ó¼º °©»ó¼±Àڱع°Áú.
  • LATS=long acting thyroid stimulator
    Áö¼Ó¼º °©»ó¼± Àڱع°Áú.
  • LTD = long term depression
    Àå±âÀû(íþÑ¢îÜ) ¾ïÁ¦(åäð¤)
  • LTP = long term potentiation
    Àå±âÀû(íþÑ¢îÜ) Ȱ¼ºÈ­(üÀàõûù)
  • Long-loop feedback
    Àåȯ(íóü») µÇ¸ÔÀ̱â
  • Long-term depression
    Àå±â(íþÑ¢) ¿ì¿ïÁõ(éØê¦ñø)
  • Long-term memory
    Àå±â±â¾ï(íþÑ¢ÑÀåã)
  • Long-term potentiation
    Àڱ⠻ó½ÂÀÛ¿ë(ßÓã«íÂéÄ)
  • Q-T prolongation syndrome ; long Q-T syndrome
    Q-T°£°Ý ¿¬ÀåÁõÈıº.
  • apical long axis view
    ½É÷ÀåÃà´Ü¸éµµ.
  • incus, long process
    ¸ð·ç°ñ±ä´Ù¸®, ħ°ñÀå°¢.
  • incus, long process of
    ħ°ñÀå°¢, ¸ð·ç°ñ±ä´Ù¸®{ÇØ}
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • course of long duration
    ±ä°æ°ú, Àå°æ°ú(íþÌèΦ).
  • incus, long process
    ¸ð·ç°ñ±ä´Ù¸®, ħ°ñÀå°¢.
  • incus, long process of
    ħ°ñÀå°¢, ¸ð·ç°ñ±ä´Ù¸®{ÇØ}
  • long (insular) gyrus
    ±ä(¼¶)À̶û
  • long TR image
    ±ä(Àå) ¹Ýº¹½Ã°£ ¿µ»ó
  • long acting
    Àå½Ã°£ÀÛ¿ë(íþãÁÊàíÂéÄ)ÀÇ, Áö¼Ó¼ºÀÇ.
  • long acting drug
    Áö¼Ó¼º¾à(ò¥áÙàõå·).
  • long acting insulin
    Áö¼Ó¼º Àν¶¸°.
  • long acting sulfonamide
    Áö¼Ó¼º ¼³ÆÄÁ¦.
  • long acting thyroid stimulator =LATS
    Àå±âÀÛ¿ë°©»ó¼±Àڱع°Áú(íþÑ¢íÂéÄ Ë£ßÒàÍô§Ð½Úªòõ).
  • long adductor muscle ³ª musculus adductor longus
    Àå³»Çâ±Ù, Àå³»Àü±Ù( íþÒ®ï®ÐÉ).
  • long arm
    ±äÆÈ, Àå¿Ï(íþèÓ).
  • long bone
    Àå°ñ(íþÍé).
  • long bone
    ±ä»À
  • long calcaneocuboid ligament
    ÀåôÀδë.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Tubular terminal part
    ´ë·ÕÁ¾¸»ºÎºÐ
    [¿¾ ¿ë¾î] °ü»óÁ¾¸»ºÎ
  • Tubular terminal portion
    ´ë·ÕÁ¾¸»ºÎÀ§
    [¿¾ ¿ë¾î] °ü»óÁ¾¸»ºÎ
  • Neuromuscular terminal of spindle
    ¹æÃ߽Űæ±ÙÀ°Á¾¸»
    [¿¾ ¿ë¾î] ¹æÃß»ó½Å°æ±ÙÁ¾¸»
  • Terminal groove
    ºÐ°è°í¶û
    [¿¾ ¿ë¾î] ºÐ°è±¸
  • Terminal sulcus
    ºÐ°è°í¶û
    [¿¾ ¿ë¾î] ºÐ°è±¸
  • Terminal crest
    ºÐ°è´É¼±
    [¿¾ ¿ë¾î] ºÐ°è¸ª
  • Terminal line
    ºÐ°è¼±
    [¿¾ ¿ë¾î] ºÐ°è¼±
  • Neuromuscular terminal
    ½Å°æ±ÙÀ°Á¾¸»
    [¿¾ ¿ë¾î] ½Å°æ±Ù¿¬Á¢Á¾¸»
  • Neurosecretory terminal
    ½Å°æºÐºñÁ¾¸»
    [¿¾ ¿ë¾î] ½Å°æºÐºñÁ¾¸»
  • Neuroepithelial terminal
    ½Å°æ»óÇÇÁ¾¸»
    [¿¾ ¿ë¾î] »óÇdz»½Å°æÁ¾¸»
  • Neuroglandular terminal
    ½Å°æ»ùÁ¾¸»
    [¿¾ ¿ë¾î] ¼±½Å°æÁ¾¸»
  • Definitive terminal plate
    ¿Ï¼ºÁ¾¸»ÆÇ
    [¿¾ ¿ë¾î] ¿Ï¼ºÁ¾ÆÇ
  • Palisade terminal
    ¿ïŸ¸®Á¾¸»
    [¿¾ ¿ë¾î] Ã¥»óÁ¾¸»
  • Primitive terminal plate
    ¿ø½ÃÁ¾¸»ÆÇ
    [¿¾ ¿ë¾î] ¿ø½ÃÁ¾ÆÇ
  • Free nerve terminal
    ÀÚÀ¯½Å°æÁ¾¸»
    [¿¾ ¿ë¾î] ÀÚÀ¯½Å°æÁ¾¸»
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • long space fibril
    ±ä°ø°£(ÍöÊà) È­À̺긱
  • long spacing segment
    ±ä°ø°£ ºÐÀý(ÍöÊàÝÂï½)
  • very long-chain fatty acids
    ¸Å¿ì ±ä »ç½½ Áö¹æ»ê(ò·Û¸ß«)
  • amino terminal
    ¾Æ¹Ì³ë¸»´Ü(ØÇÓ®)
  • carboxyl terminal
    Ä«¸£º¹½Ç¸»´Ü(ØÇÓ®)
  • C-terminal
    C-¸»´Ü(ØÇÓ®)
  • N-terminal
    (å²) N-¸»´Ü (ØÇÓ®)
  • terminal
    ¸»´Ü(ØÇÓ®)
  • 3'-terminal
    3'¸»´Ü(ØÇÓ®)
  • 5'-terminal
    5'¸»´Ü(ØÇÓ®)
  • terminal deletion
    ¸»´Ü°á¼Õ (ØÇÓ®ÌÀáß)
  • terminal deoxynucleotidyl transferase
    ¸»´Ü(ØÇÓ®)µð¿Á½Ã´©Å¬·¹¿ÀŸÀÌµå Æ®¶õ½ºÆÛ·¹À̽º
  • terminal enzyme
    ¸»´ÜÈ¿¼Ò (ØÇÓ®ý£áÈ)
  • terminal redundancy
    ¸»´ÜÁߺ¹ (ØÇÓ®ñìÜÜ)
  • terminal repetition
    ¸»´Ü¹Ýº¹ (ØÇÓ®ÚãÜÖ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ter rub [Lat. tere]; terminal [end of chromosome]; terminal or end; ternary; tertiary; three times; thre...
TML terminal midline; terminal motor latency; tetramethyl lead
LA lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left...
HIV Human Immunodeficiency Virus
CD4 HIV helper cell count
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HIV- HIV negative
HIV+ HIV positive
HIV Pr HIV protease
HIV- HIV sero-negative
HIV+ HIV seropositive
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • long history
    ¿À·¡µÈ º´·Â
  • long pin porcelain facing
    Àåħ ÀüÀå µµÄ¡
  • long sight
    ¿ø½Ã
    µ¿ÀǾî=hy
  • long term illness
    Àå±â Áúȯ
  • long tract syndrome
    Àå°æ·Î ÁõÈıº
  • long-acting nitrates
    Àå½Ã°£ ÀÛ¿ëÇÏ´Â Áú»ê¿°
  • long-standing
    Àå±âÀÇ
  • long-term exposure
    Àå±â ³ëÃâ
  • biogenic amine terminal
    »ýü³» ¾Æ¹Î Á¾¸», »ý¿ø¼º ¾Æ¹Î Á¾¸», »ý¹°¼º ¾Æ¹Î Á¾¸»
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • lingual terminal sulcus
    ¼³ ºÐ°è±¸
  • nerve terminal
    ½Å°æ Á¾¸»
  • nociceptor terminal
    Ä§ÇØ ¼ö¿ëü ¸»´Ü, À¯ÇØ ¼ö¿ë±â ¸»´Ü
  • primary afferent terminal
    ÀÏÂ÷ ±¸½É¼º ¸»´Ü
  • reticulothalamic terminal
    ¸Á»ó ½Ã»ó ¸»´Ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chronic symptomatic HIV infection This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening.
Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss.
This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc).
(27 Sep 1997)
middle stage HIV disease <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening.
Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc).
(27 Sep 1997)
primary HIV infection <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands.
(06 Mar 1998)
HIV <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified.
Type 1: the retrovirus recognised as the agent that induces AIDS.
Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa.
Acronym: HIV
(11 Nov 1997)
HIV-1 The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte.
(12 Dec 1998)
HIV-1 reverse transcriptase <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1.
Registry number: EC 2.7.7.-
(12 Dec 1998)
HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian lentivirus siv and infects only t4-lymphocytes expressing the CD4 phenotypic marker.
(12 Dec 1998)
HIV-2 protease <enzyme> Processes hiv-1pr53(gag) and analogous junction peptides in vitro; less than 60% amino acid identity to hiv-1 protease
Registry number: EC 3.4.23.-
Synonym: hiv2 protease
(26 Jun 1999)
HIV-2 reverse transcriptase <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91)
Registry number: EC 2.7.7.-
(26 Jun 1999)
HIV antibodies Antibodies reactive with human immunodeficiency virus (HIV, previously called HTLV-III/lav) antigens of aids. This includes HIV-1 antibodies and HIV-2 antibodies.
(12 Dec 1998)
HIV antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens.
(12 Dec 1998)
HIV core protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.
(12 Dec 1998)
HIV encephalopathy <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting.
Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection.
(09 Oct 1997)
HIV enhancer Cis-acting regulatory sequences in the HIV long terminal repeat (ltr) which play a major role in induction or augmentation of HIV gene expression in response to environmental stimuli such as mitogens, phorbol esters, or other viruses. The HIV enhancer is the binding site for many cellular transcription factors including the nuclear factor nf-kappa b.
(12 Dec 1998)
HIV enteropathy Chronic, well-established diarrhoea (greater than one month in duration) without an identified infectious cause after thorough evaluation, in an HIV-positive individual. It is thought to be due to direct or indirect effects of HIV on the enteric mucosa. HIV enteropathy is a diagnosis of exclusion and can be made only after other forms of diarrhoeal illness have been ruled out.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • before long
    °ð
  • long
    ±ä,±æ°Ô,¿À·§µ¿¾È,¿µ±¸È÷
  • long for
    °¥¸ÁÇÏ´Ù
  • long-distance call
    Àå°Å¸®(½Ã¿Ü)ÀüÈ­
  • long-drawn
    ±æ°Ô ´ÃÀÎ
  • long-drawn-out
    ±æ°Ô ´ÃÀÎ
  • so long !
    ¾È³ç
  • so long as ~
    ~ÇÏ´Â µ¿¾È,~ÇÏ´ÂÇÑ,~Çϱ⸸ Çϸé
  • E.long.
    east longitude
  • Long Beach
    ¹Ì±¹ Los Angeles ±Ù±³ÀÇ µµ½Ã;ÇØ¼ö¿åÀå
  • Long Island
    ·Õ ¼¶(¹Ì±¹ New YorkÁÖ ³²µµºÎÀÇ ¼¶)
  • Long Island Slund
    ·Õ ¾Æ¸±·£µå »ç¿îµå
  • Long John
    Ű´Ù¸®
  • Long March
    (the~)(Áß±¹ °ø»ê´çÀÇ)´ë ÀåÁ¤
  • Long Tom
    Àå°Å¸®Æ÷
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á